ASCO 2022 - Chicago - Chronic Myeloid Leukemia
NEWS
Hematology Highlights From ASCO 2022
July 22, 2022, The ASCO Post
Longer Deep Molecular Remission in CML Associated With Treatment-Free Remission
June 15, 2022, Cancer Therapy Advisor
Trends in Second Malignancy and Mortality Risk After Primary Chronic Myeloid Leukemia
June 15, 2022, Cancer Therapy Advisor
Use of Oral Tyrosine Kinase Inhibitors for R/R CML Increasing Over Time
June 15, 2022, Cancer Therapy Advisor
CML Does Not Affect Antibody Development Against SARS-CoV-2
June 15, 2022, Cancer Therapy Advisor
Ponatinib Plus Blinatumomab for Patients With Philadelphia Chromosome–Positive ALL
June 13, 2022, The ASCO Post
Benefit of Asciminib Transforms Standard of Care for Patients With CML in Chronic Phase
June 10, 2022, Targeted Oncology
SOME INTERESTING ABSTRACTS ABOUT CML
Trends in Medicare oral anticancer drug utilization among relapsed and refractory chronic myeloid leukemia patients.
Antibody seroprevalence against SARS-Cov-2 among chronic myeloid leukemia patients.
Imatinib may not be the best choice for planning TFR in CML patients.
Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial.
Efficacy and safety of bosutinib in later-line patients (pts) with chronic myeloid leukemia (CML): A sub-analysis from the phase 4 BYOND trial.
Treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) following the discontinuation of tyrosine kinase inhibitors.
Profile and survival outcomes among patients with second malignancies following a primary chronic myeloid leukemia: An analysis of the SEER database (1975-2016).
Trends in Medicare oral anticancer drug utilization among relapsed and refractory chronic myeloid leukemia patients.
Antibody seroprevalence against SARS-Cov-2 among chronic myeloid leukemia patients.
Imatinib may not be the best choice for planning TFR in CML patients.
Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial.
Efficacy and safety of bosutinib in later-line patients (pts) with chronic myeloid leukemia (CML): A sub-analysis from the phase 4 BYOND trial.
Treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) following the discontinuation of tyrosine kinase inhibitors.
Profile and survival outcomes among patients with second malignancies following a primary chronic myeloid leukemia: An analysis of the SEER database (1975-2016).
